A Phase 3 interventional study of Doxycyline Hyclate tablet and Vibramycin (doxycyline hyclate) capsule in Urogential Chlamydia Trachomatis Infection, sponsored by Warner Chilcott. Completed at 43 sites in United States. Open to participants aged 19 Years to 45 Years. Per ClinicalTrials.gov, last updated 2012-01-27.
Sponsored by Warner Chilcott (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Chlamydia Infections with a site in United States — 8 open to participants now, 8 under way, none of them phase 3. Chlamydia Infections · United States.
Among the 79 studies in Chlamydia Infections with a site in United States, this one is the 29th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2010, is one of 9 in phase 3, and was the 24th registered.
134 studies on the registry are indexed under Chlamydia Infections; 23 are open to participants now.
Browse Chlamydia Infections studies →8 of the 79 studies in Chlamydia Infections with a site in United States are open now. Recruiting first, the newest first:
Westat · Sites in United States
Ages 13–29 · Women only
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 16–24
Tulane University · Sites in United States
Ages 15–26 · Healthy volunteers
Queen's Medical Center · Sites in United States
Ages 14+ · Women only · Healthy volunteers
Northwestern University · Sites in United States
Ages 16–34 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Chlamydia Infections studies recruiting now, 6 (43%) set no upper age limit and 7 (50%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 19 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 9 · Phase 4 9
First in 1999; this study’s year is marked. 5 started in 2010.
This study's enrollment of 495 is below the median of 600 across 94 interventional studies indexed under Chlamydia Infections.
Median enrollment 511 across the 56 interventional studies, 373 across the 22 observational. Of the 67 that completed or were terminated, 21 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 79 have an industry lead sponsor. The 10 most frequent:
This study is registered under Warner Chilcott, one of the names counted as AbbVie. Under that name alone:
Warner Chilcott is the lead sponsor of 58 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
AbbVie has 1 study filed under Chlamydia Infections — fewer than ten, so there is no comparison to draw.
2 of the studies in Chlamydia Infections with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06844045Icahn School of Medicine at Mount SinaiPoint of Care STI Testing | 2026-12-31 |
| NCT06951438Queen's Medical CenterAssessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortion Provision | 2027-01-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 79 studies in Chlamydia Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluate the clinical efficacy and safety of WC2031 200 mg tablets taken orally once a day for 7 days versus Vibramycin (doxycycline) 100 mg capsules taken orally twice a day for 7 days, for the treatment of uncomplicated urogenital Chlamydia trachomatis infection. Primary efficacy endpoint is microbiological cure at Day 28. Safety assessments are adverse events, changes in vital signs and laboratory test results.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once daily
Drug: Doxycyline Hyclate tablet
Twice daily
Drug: Vibramycin (doxycyline hyclate) capsule
200 mg tablet, once daily for 7 days
Also known as: WC2031
100 mg capsule, twice daily for 7 days, over-encapsulated
Also known as: doxycycline
Microbiological Cure Rate
Percentage of Subjects in mITT Population with Microbiological Cure defined as a negative result for C. trachomatis as determined by GP AC2 NAAT (Gen-Probe Aptima Combo 2 Nucleic Acid Amplification Test) at Day 28
Time frame: Day 28
Microbiological Cure and Clinical Cure of C. Trachomatis, Day 28, Clinically Evaluable Population, Percentage Participants Cured
Microbiological cure (defined as a negative result for urogenital C. trachomatis, determined by GP AC2 NAAT/Gen-Probe Aptima Combo 2 Nucleic Acid Amplification Test and clinical cure (for males defined as resolution of baseline signs/symptoms of dysuria, urethral pruritus and urethral discharge, and resolution of exam finding of urethral discharge; for females resolution of exam finding of endocervical discharge) at Day 28
Time frame: End of Study (Day 28)
Microbiological Cure C. Trachomatis and M. Genitalium, M. Genitalium Coinfected Population, Day 28, Percentage Participants Cured
Percentage Subjects Cured of both M. genitalium and C. trachomatis M. genitalium co-infected population: microbiological cure for both at Day 28, defined as negative PCR (polymerase chain reaction) for M. genitalium and negative GP AC2 NAAT (Gen-Probe Aptima Combo 2 Nucleic Acid Amplification test) for C. trachomatis at Day 28
Time frame: End of Study (Day 28)
Microbiological Cure C. Trachomatis, N. Gonorrhoea Negative Population, Day 28, Percentage Participants Cured
Percentage Participants cured in N. gonorrhoea Negative Population: cured defined as both microbiological cure (negative result for urogenital C. trachomatis, determined by GP AC2 NAAT/Gen-Probe Aptima Combo 2 Nucleic Acid Amplification test) and clinical cure (males defined as resolution of baseline signs/symptoms of dysuria, urethral pruritis and urethral discharge, and resolution of exam finding of urethral discharge; females - resolution of exam finding of endocervical discharge) at Day 28
Time frame: Day 28
Enrollment period began 7 Apr '10
| Milestone | Doxycycline Hyclate | Vibramycin |
|---|---|---|
| Started | 247 | 248 |
| Safety population | 246 | 248 |
| Mitt population | 188 | 190 |
| Completed | 228 | 231 |
| Not completed | 19 | 17 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Lost to follow-up | 12 | 9 |
| Withdrew: Various | 2 | 4 |
| Withdrew: Withdrawal by subject | 3 | 0 |
Percentage of Subjects in mITT Population with Microbiological Cure defined as a negative result for C. trachomatis as determined by GP AC2 NAAT (Gen-Probe Aptima Combo 2 Nucleic Acid Amplification Test) at Day 28
| percentage of participants cured | Doxycycline Hyclate | Vibramycin |
|---|---|---|
| Microbiological Cure Rate | 94.9 (91.5 to 98.3) | 94.6 (91.2 to 98.0) |
Microbiological cure (defined as a negative result for urogenital C. trachomatis, determined by GP AC2 NAAT/Gen-Probe Aptima Combo 2 Nucleic Acid Amplification Test and clinical cure (for males defined as resolution of baseline signs/symptoms of dysuria, urethral pruritus and urethral discharge, and resolution of exam finding of urethral discharge; for females resolution of exam finding of endocervical discharge) at Day 28
| Percentage Particpants Cured | Doxycycline Hyclate | Vibramycin |
|---|---|---|
| Microbiological Cure and Clinical Cure of C. Trachomatis, Day 28, Clinically Evaluable Population, Percentage Participants Cured | 80.0 | 68.6 |
Percentage Subjects Cured of both M. genitalium and C. trachomatis M. genitalium co-infected population: microbiological cure for both at Day 28, defined as negative PCR (polymerase chain reaction) for M. genitalium and negative GP AC2 NAAT (Gen-Probe Aptima Combo 2 Nucleic Acid Amplification test) for C. trachomatis at Day 28
| Percentage Participants Cured | Doxycycline Hyclate | Vibramycin |
|---|---|---|
| Microbiological Cure C. Trachomatis and M. Genitalium, M. Genitalium Coinfected Population, Day 28, Percentage Participants Cured | 38.5 | 18.2 |
Percentage Participants cured in N. gonorrhoea Negative Population: cured defined as both microbiological cure (negative result for urogenital C. trachomatis, determined by GP AC2 NAAT/Gen-Probe Aptima Combo 2 Nucleic Acid Amplification test) and clinical cure (males defined as resolution of baseline signs/symptoms of dysuria, urethral pruritis and urethral discharge, and resolution of exam finding of urethral discharge; females - resolution of exam finding of endocervical discharge) at Day 28
| Percentage Participants Cured | Doxycycline Hyclate | Vibramycin |
|---|---|---|
| Microbiological Cure C. Trachomatis, N. Gonorrhoea Negative Population, Day 28, Percentage Participants Cured | 94.9 (91.4 to 98.3) | 94.6 (91.2 to 98.0) |
Collected over 28 day treatment period. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Doxycycline Hyclate | — | 0/246 (0%) | 84/246 (34.1%) |
| Vibramycin | — | 0/248 (0%) | 129/248 (52%) |
| Event | Doxycycline Hyclate | Vibramycin |
|---|---|---|
| NauseaGastrointestinal disorders | 33/246 | 51/248 |
| VomitingGastrointestinal disorders | 20/246 | 30/248 |
| HeadacheNervous system disorders | 5/246 | 15/248 |
| Abdominal Pain UpperGastrointestinal disorders | 5/246 | 13/248 |
| DiarrhoeaGastrointestinal disorders | 8/246 | 11/248 |
| Vaginitis BacterialInfections and infestations | 8/246 | 5/248 |
| Vulvovaginal Mycotic InfectionInfections and infestations | 5/246 | 4/248 |
| Age Continuous(years) | Doxycycline Hyclate | Vibramycin | Total |
|---|---|---|---|
| Mean | 24.1 ± 4.9 | 23.9 ± 4.9 | 24.0 ± 4.9 |
| Age, Customized(participants) | Doxycycline Hyclate | Vibramycin | Total |
|---|---|---|---|
| <30 years | 163 | 170 | 333 |
| Between 30 and 40 years | 22 | 18 | 40 |
| >40 years | 3 | 2 | 5 |
| Gender(participants) | Doxycycline Hyclate | Vibramycin | Total |
|---|---|---|---|
| Female | 115 | 118 | 233 |
| Male | 73 | 72 | 145 |
| Ethnicity (NIH/OMB)(Participants) | Doxycycline Hyclate | Vibramycin | Total |
|---|---|---|---|
| Hispanic or Latino | 33 | 44 | 77 |
| Not Hispanic or Latino | 155 | 146 | 301 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Doxycycline Hyclate | Vibramycin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 3 |
| Asian | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 3 | 1 | 4 |
| Black or African American | 109 | 104 | 213 |
| White | 61 | 73 | 134 |
| More than one race | 10 | 10 | 20 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Doxycycline Hyclate | Vibramycin | Total |
|---|---|---|---|
| United States | 247 | 248 | 495 |
The record gives a start of Apr 2010, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doxycycline